BioSight
Companies
Apogee Therapeutics, Inc. logo

APGE

NASDAQWALTHAM, MA
Apogee Therapeutics, Inc.

Apogee Therapeutics is a clinical-stage biotech company developing monoclonal antibodies designed to treat inflammatory and immunology conditions including atopic dermatitis, asthma, eosinophilic esophagitis, and COPD. The pipeline consists of four validated antibody targets being tested as both standalone treatments and combination therapies, with lead program zumilokibart (APG777), an anti-IL-13 antibody showing a 77-day half-life that could enable dosing every three to six months. Zumilokibart is currently in Phase 2 trials for atopic dermatitis, with other programs in earlier-stage development.

Price history not yet available for APGE.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar